Invivo CAR-T
Phase 1Cell therapy
Invivo CAR-T is one of 23 biologic programs targeting Relapsed or Refractory Multiple Myeloma (RRMM). It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in B Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Trexall
Jazz PharmaceuticalsPhase 3
Oncovin
Eli LillyPhase 3
Blincyto
AmgenPhase 3
Adriamycin
PfizerPhase 3
Rituxan
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Purinethol
SStason
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Oncaspar
SServier
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
B Acute Lymphoblastic Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Invivo CAR-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details